Impact Emotional Intelligence Program on Opioid Relapse

A Prospective Study of the Impact of an Emotional Intelligence Program on Opioid Relapse and Its Determinants

Addiction is the repeated and increased use of a substance, the deprivation of which gives rise to symptoms of distress and an irresistible urge to use the agent again and which leads also to physical and mental deterioration. The concept of emotional intelligent (EI) "the ability to perceive accurately, appraise and express emotion; the ability to access and generate feelings when they facilitate thought; the ability to understand emotion and emotional knowledge; and the ability to regulate emotions to promote emotional and intellectual growth". Most drug addicts possess hidden defects in their social skills, and do not have good relations with their peers.

Study Overview

• Status: Completed
• Conditions: Opioid Use Disorder; Emotional Intelligence
• Intervention / Treatment: Behavioral: emotion intelligence program

Detailed Description

Addiction is the repeated and increased use of a substance, the deprivation of which gives rise to symptoms of distress and an irresistible urge to use the agent again and which leads also to physical and mental deterioration. Continued opioid misuse can result in syndromes of abuse and dependence and cause disturbances in mood, behavior, and cognition that can mimic other psychiatric disorders. Opioid addiction affects the young and the old, the wealthy and the poor, and the professional and the unemployed.

The concept of emotional intelligent (EI) "the ability to perceive accurately, appraise and express emotion; the ability to access and generate feelings when they facilitate thought; the ability to understand emotion and emotional knowledge; and the ability to regulate emotions to promote emotional and intellectual growth", the ability to manage and regulate emotions in an effective manner and ability to be sufficiently optimistic, positive and self- motivated in order to set and achieve goals.

Most drug addicts possess hidden defects in their social skills, and do not have good relations with their peers. The other possible causes of orienting toward drugs are defects in problem solving, stress-management, and prevention from dangerous and impulsive behaviors.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Egypt
  • Assiut, Egypt
    • Faculty of Nursing

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• in opioid groups: only opioid addiction
• in healthy groups: no history of psychiatric illness or substance use

Exclusion Criteria:

• have medical conditions

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Participants with opioid use disorder group with emotion intelligence program (n=20); Participants with opioid use disorder group who had emotion intelligence program to increase aware about definition, component, how to deal with EI to reduce relapse rate.	Behavioral: emotion intelligence program; The programme was established using research that described emotional intelligence components and their applicability to patients suffering from substance abuse. it considers as awareness program.
No Intervention: Participants with opioid use disorder group without intelligence program (n=20).; Participants with opioid use disorder group who had traditional medical treatment only
No Intervention: A healthy group (n=20) served as a control group.; A healthy group who did not have history of psychiatric illness or substance use.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
develop an EI programme to prevent relapses in addiction.	An emotional intelligence (EI) program was developed and implemented for patients in the hospital. Emotion intelligence scale was measured at baseline prior to starting the EI program. The EI program was then administered to patients during their hospital stay. Emotion intelligence scale assessments were conducted at discharge from the hospital and again 3 months after discharge. Regarding EI program sessions took place in the recreation hall, where material such as videos and booklets containing content on emotional intelligence skills was presented.	through study completion, an average of 1 year
measure level of emotion intelligence in opioid addiction	Measure the level of emotional intelligence. The scale consists of sixty objects classified into six distinct domains. A four-point Likert scale is employed, which spans from 1 (indicating never) to 4 (indicating always). The percentages represent the scores; emotional intelligence ranges (from 0-100%), and higher scores mean a high level of emotional intelligence.	through study completion, an average of 1 year

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Study Director: gellan Karamallah R Ahmed, Assiut University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2022
• Primary Completion (Actual): November 1, 2022
• Study Completion (Actual): November 1, 2023

Study Registration Dates

• First Submitted: December 17, 2023
• First Submitted That Met QC Criteria: January 3, 2024
• First Posted (Actual): January 16, 2024

Study Record Updates

• Last Update Posted (Estimated): January 17, 2024
• Last Update Submitted That Met QC Criteria: January 14, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Substance-Related Disorders; Narcotic-Related Disorders; Opioid-Related Disorders
• Other Study ID Numbers: EMOTION INTELLIGENCE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No